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Abstract
Thrombopoietin (TPO) and its receptor, MPL, are the primary regulators of platelet production 
and critical for hematopoietic stem cell (HSC) maintenance. Since TPO was first cloned in 1994, 
the physiological and pathological roles of TPO and MPL have been well characterized, 
culminating in the first MPL agonists being approved for the treatment of chronic immune 
thrombocytopenia in 2008. Dysregulation of the TPO-MPL signaling axis contributes to the 
pathogenesis of hematological disorders: decreased expression or function results in severe 
thrombocytopenia progressing to bone marrow failure, while hyperactivation of MPL signaling, 
either by mutations in the receptor or associated Janus kinase 2 (JAK2), results in pathological 
myeloproliferation. Despite its importance, it was only recently that the long-running debate 
over the mechanism by which TPO binding activates MPL has been resolved. This review will 
cover key aspects of TPO and MPL structure and function and their importance in receptor 
activation, discuss how these are altered in hematological disorders and consider how 
a greater understanding could lead to the development of better-targeted and more effica-
cious therapies.
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Introduction
Thrombopoietin (TPO) was first described in the late 1950s as 
a humoral factor induced in response to thrombocytopenia and 
capable of increasing circulating platelet count[1]. Despite many 
attempts to isolate and clone TPO, the hormone remained elusive 
until 1986, when the seemingly unrelated discovery of the mye-
loproliferative leukemia virus (v-MPL), a retrovirus that causes 
acute leukemia and polycythemia in mice[2], provided a clear 
path for the isolation and characterization of TPO several years 
later. Subsequent analysis of v-MPL and its cellular homologue, 
MPL, revealed it to be a member of the type I cytokine receptor 
family and the likely receptor for TPO [3,4]. Aided by the cloning 
of MPL, several groups successfully cloned and isolated TPO in 
1994 [5–8].
Research over the following two decades revealed TPO-MPL 
as a key hematopoietic cytokine signaling complex, not only for 
the regulation of megakaryocyte differentiation and platelet 
homeostasis, but also for hematopoietic stem cell (HSC) self- 
renewal and proliferation. The therapeutic potential of TPO was 
realized in 2008 with the clinical approval of two MPL agonists, 
romiplostim[9] and eltrombopag[10] for the treatment of chronic 
immune thrombocytopenia (ITP) and later for aplastic anemia.
Despite their role in biology and medicine, the mechanisms of 
TPO-MPL interaction and activation are not wholly understood. 
Defining these interactions and how they are altered in hemato-
logical disorders, such as the myeloproliferative neoplasms and 
thrombocytopenias, could aid the identification and development 
of novel therapeutic agents. Indeed, recent evidence highlights the 
remarkable complexity of receptor activation in both physiologi-
cal and pathological contexts [11–13]. These findings may in turn 
generate new possibilities for fine-tuning signaling outputs from 
MPL, allowing greater and more precise control of HSC main-
tenance and megakaryocyte differentiation.
Thrombopoietin
The human THPO gene encodes a secreted protein composed of 
a signal peptide followed by two functional domains; an 
N-terminal MPL-binding domain and a C-terminal, so-called 
glycan domain (Figure 1a). The crystal structure of the 
N-terminal domain of TPO reveals a classical 4-helix bundle, 
similar to erythropoietin (EPO) and growth hormone (GH), held 
together by two conserved disulfide bridges[14] (Figure 1b). In 
common with EPO and GH, TPO has two non-identical binding 
sites for its receptor; a high-affinity site (site 1) with binding 
affinity K1 in the nanomolar range, and a lower affinity site 
(site 2) with binding affinity K2 in the micromolar range[14] 
(Figure 1(b-c)). These are located on opposite sides of the 4-heli-
cal bundle, such that the active signaling complex comprises one 
molecule of TPO bound to two molecules of MPL (Figure 2(a- 
b)). It is important to note that the binding affinities reported by 
Feese and colleagues[14] were measured in solution, using 
recombinant, soluble, monomeric receptor ectodomain and the 
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MPL-binding domain of TPO, and thus may not accurately reflect 
the situation in cells. In particular, the three-dimensional K2 
measured in solution may underestimate the true binding affinity 
on cells, which is a two-dimensional binding event (see below and 
Figure 2a). Characterization of the impact of homology model- 
based site-directed mutants of TPO on MPL binding and cellular 
proliferation, as well as biophysical characterization of TPO and 
its competing interactions with soluble MPL and neutralizing 
antibodies, confirmed the two-step assembly model, in which 
site 1 mediates the binding of the first MPL monomer, whilst 
site 2 is required for interaction with a second monomer to form 
a ternary complex that is competent for downstream signaling. 
Mutations in the predicted site 1 reduced affinity for MPL in 
a phage ELISA, whilst those in the predicted site 2 were permis-
sive for MPL binding, but showed reduced specific activity in 
proliferation assays [14,17–20]. Similarly, the epitope for neutra-
lizing antibodies that blocked both initial binding of TPO to MPL 
and bioactivity mapped to the predicted site 1, whilst neutralizing 
antibodies that did not prevent receptor association bound to an 
epitope in the predicted site 2 (see below)[17]. Interestingly, 
levels of TPO in plasma and serum from healthy individuals 
[21–23] are more than 1000-fold below the values of K1 mea-
sured in vitro[14] and cells[11]. This suggests that under normal 
physiological conditions, the majority of receptors on the cell 
surface will not be bound to TPO. Of note, the reported values 
of TPO in serum and plasma may not be representative of the 
levels of TPO in the bone marrow milieu nor of the local con-
centration of TPO at the cell surface.
In contrast to EPO and GH, TPO possesses an additional, 
predicted intrinsically disordered C-terminal domain, which is 
heavily glycosylated (six N-linked and four O-linked sites)[24]. 
The glycan domain plays a role in correct trafficking of the 
cytokine through the secretory system [25,26].
TPO is primarily expressed in the liver [27,28] and levels of 
circulating TPO are controlled by multiple regulatory mechan-
isms, from transcription (promoter usage and alternative splicing) 
Figure 1. Schematic representations of TPO 
and MPL proteins. (A) Domain diagrams 
showing selected gain-of-function (GOF) and 
loss-of-function (LOF) mutations, conserved 
sequence motifs and post-translational modifi-
cations. The helices of the MPL-binding domain 
within TPO are labeled hA through hD. SP 
(signal peptide), CRM (cytokine receptor mod-
ule), TM (transmembrane domain). (B) Ribbon 
representation of the 4-helical bundle MPL- 
binding domain of human TPO with the N- and 
C-termini facing away from the viewer, such 
that the two MPL-binding sites are shown to the 
left and right respectively. Helices are labeled as 
in A. The four conserved cysteines and three 
arginines mutated in hereditary thrombocytope-
nia are labeled and drawn in ball-and-stick 
representation (carbon atoms in dark gray, 
nitrogen in blue, sulfur in yellow). (C) 
Molecular surface of the MPL-binding domain 
of TPO colored according to predicted high 
(site 1) and low (site 2) affinity binding sites for 
MPL[14]. The MPL-binding sites are highly 
conserved and lie on opposing faces of TPO. 
Residues mutated in hereditary thrombocytope-
nia are indicated. Views are rotated 180º with 
respect to one another. Panel A prepared using 
Illustrator for Biological Sequences[15]; panels 
B-C prepared using chain V from PDB 1V7M 
[14], and CCP4MG[16]. Residues are numbered 
according to the human TPO and MPL precur-
sor proteins with Uniprot IDs P40225 and 
P40238, respectively.
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and translation[29] through secretion and ultimately clearance. 
Physiological levels of plasma TPO are usually inversely 
proportional to platelet count, although sensing mechanisms reg-
ulating TPO production and release by the liver remain 
Figure 2. MPL receptor dimerization characteristics. Two-step assembly mechanism (A) for the formation of active homodimeric signaling 
complexes accounts for the (B) bell-shaped TPO dose-response curve. At physiological receptor densities and in the absence of TPO (gray), MPL 
(pink) and the associated intracellular JAK2 (blue) are monomeric and inactive. At low concentrations of TPO (below K1 or K
3D
D), most MPL at the 
cell surface are not bound to TPO (and are thus monomeric (M) and inactive), whilst a small number are bound to TPO in a binary (1:1), non-signaling 
competent complex. As the concentration of TPO rises, the proportion of binary complexes on the cell surface increases, and there is an increased 
likelihood that these will encounter a second MPL monomer and form a ternary (2:1 MPL:TPO), active complex (D) with the 2-dimensional binding 
affinity K2 (or K
2D
D). Ternary complex formation and downstream signaling (indicated by yellow ‘lightning’) reach a maximum when the 
concentration of TPO equals K1. Finally, as the concentration of TPO exceeds K1, MPL monomers become saturated with TPO and binary non- 
signaling complexes (M) predominate. The two different MPL-binding sites on TPO are colored as in Figure 1, in light and dark purple, respectively. 
Panel B is a theoretical representation of the bell-shaped dose-response curve. (C, D) Enhanced receptor dimer stability, as a result of oncogenic 
mutations in MPL and/or JAK2 leads to the TPO-independent signaling that underlies thrombocytic disease. Increased receptor density also leads to 
MPL dimer formation in the absence of cytokine. Panel C prepared using data from[11]
Figure 3. Expression, function and regulation of TPO. TPO is mainly produced in the liver and to a lesser extent in the kidneys. Once released into 
the circulation TPO drives megakaryocyte differentiation in the bone marrow, increasing the numbers of circulating platelets (A). There are currently 
two proposed mechanisms of TPO regulation. The “platelet sponging theory” (B) postulates that MPL on platelets bind circulating TPO, inducing 
internalization and degradation of the complex, thereby allowing circulating platelets to directly influence megakaryopoiesis and production of new 
platelets. A more recent model (C) suggests that changes in surface glycan composition in aged or senescent platelets promotes their removal; 
desialylated platelets interact with Ashwell-Morrell receptors on hepatocytes, activating Janus kinase (JAK)/signal transducer and activator of 
transcription (STAT) signaling pathways to increase THPO transcription. HSC (hematopoietic stem cell), CMP (common myeloid progenitor), MEP 
(megakaryocyte erythrocyte progenitor), MKB (megakaryoblast), MK (megakaryocyte), PLT (platelet).
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controversial [30–32]. It is likely, however, that a combination of 
these mechanisms (detailed in Figure 3) is responsible for the 
regulation of plasma TPO levels.
Thrombopoietin Receptor - MPL
Along with the EPO, GH and prolactin (PRL) receptors, MPL 
(also called CD110 or TPOR) belongs to the group 1 cytokine 
receptor sub-family, and comprises an extracellular cytokine- 
binding domain linked via a transmembrane spanning helix to 
a cytosolic domain that serves as a binding site for intracellular 
signaling proteins [33,34] (Figure 1a). Critically, these receptors 
lack intrinsic kinase activity, instead relying on interactions with 
JAK proteins to initiate intracellular signaling. In the case of 
MPL, signaling is predominantly driven through JAK234.
In contrast to EPOR, GHR and PRLR, no experimental struc-
tures are available for MPL in the public domain, although an all- 
atom molecular dynamics simulation of the membrane-embedded 
MPL transmembrane and intracellular domains (TM-ICD) in 
complex with JAK2 was published [11]. The MPL extracellular 
domain (ECD) differs from EPOR in that it comprises two, rather 
than one, cytokine receptor modules. Each cytokine receptor 
module (CRM) consists of two subdomains, the first of which 
adopts an immunoglobulin (Ig)-like fold, and contains four con-
served cysteine residues which form two disulfide bridges, whilst 
the second resembles a fibronectin type III (FnIII) domain, and 
contains a WSXWS motif, characteristic of the cytokine receptor 
family [33,35]. By analogy with EPOR, along with mutational 
studies, the TPO-binding site is predicted to be primarily located 
in the first cytokine receptor module (CRM1) at the intersection 
between subdomains [36,37]. Sequence homology suggests that 
the overall structures of both CRM1 and CRM2 will resemble that 
of the EPOR ECD; however, the relative orientations of CRM1 
and CRM2 with respect to one another and the plasma membrane 
remain unclear.
The MPL ECD is connected to the intracellular domain (ICD) 
via a single-pass transmembrane (TM) helix flanked by juxta-
membrane (JM) regions. Spectroscopic studies of monomeric JM- 
TM peptides in lipid bilayers are consistent with a ‘split’ helical 
structure in which the extracellular JM sequence forms a short 
helix lying parallel to the plane of the membrane, whilst the TM 
helix is tilted with respect to the membrane normal [38,39]. Upon 
dimerization, the ‘split’ helices appeared to coalesce and their tilt 
angle reduced[39]. These and earlier studies identified a binding 
site for the MPL agonist, eltrombopag, within the TM helical 
region, most likely in the vicinity of H49910 [38–40].
The MPL ICD is predicted to be largely intrinsically disor-
dered in the absence of binding partners[41]. Tyrosines in the 
ICD are phosphorylated upon receptor activation (Figure 1a) and 
recruit signal transduction proteins to the membrane and/or within 
proximity of JAK2. JAK2 associates with MPL via binding of the 
JAK2 FERM-SH2 domain to the MPL Box 1 and 2 sequences 
(Figure 1a), which were mapped via mutational studies[42]. The 
binding affinity of the ICD peptide for JAK2 in solution has yet to 
be determined, and the stability of this interaction appears to be 
critically dependent on the presence of the plasma membrane. In 
addition to interacting with MPL, the JAK2 FERM-SH2 domain 
anchors the receptor/kinase complex to the plasma membrane via 
electrostatic and hydrophobic interactions[11]. Three tyrosines 
(Y591, Y626 and Y631) located at the distal end of the ICD are 
rapidly phosphorylated in response to TPO stimulation [43,44]. 
Y626 is the primary phosphorylation site, whereas Y631 is 
a secondary site; both sites are required for maximal TPO- 
mediated proliferation and activation of downstream signal trans-
duction [44–46]. Conversely, phosphorylation of Y591 appears to 
down-regulate MPL activity by limiting receptor activation[43] 
and driving receptor internalization[47].
MPL is expressed by HSCs from the earliest stage of devel-
opment[48] and is critical for megakaryocyte development[50]. 
Decreased receptor expression or function can cause severe 
thrombocytopenia in humans[49], a phenotype recapitulated by 
Mpl-null mice, which have only ~5-10% the number of megakar-
yocytes and circulating platelets compared to wild-type animals 
[50]. Evidence suggests the primary role of TPO-MPL is to 
promote megakaryocyte lineage selection in myeloid progenitor 
cells, rather than differentiation of more mature megakaryocytes. 
In mice, ablation of Mpl specifically in the megakaryocyte lineage 
(Mpl-floxed/Pf4cre) not only failed to reduce platelet count, but 
actually drove myeloproliferation, presumably as a consequence 
of ineffective TPO clearance due to absence of MPL on platelets 
[51]. Interestingly, there is also some evidence that TPO may 
prime platelets for activation. Increased levels of plasma TPO in 
patients with unstable angina appears to increase monocyte- 
platelet aggregates and enhances platelet aggregation in response 
to certain agonists [52,53]. Fortunately, however, there is no 
evidence of an increased risk of thrombosis in patients receiving 
TPO agonists [54,55].
Mechanisms of MPL Activation by TPO
There is some debate in the literature as to whether TPO drives 
activation of MPL via receptor dimerization or by inducing con-
formational changes in a pre-formed receptor dimer. In this sec-
tion, we will try to consolidate previously published work to 
suggest a feasible model of receptor activation.
Early work provided two lines of evidence in support of TPO- 
mediated MPL dimer formation driving signaling; cysteine muta-
tions at a proposed dimer interface resulted in constitutive activa-
tion[56], whilst the Fab fragments of agonist monoclonal[57], and 
polyclonal antibodies[58] could not support cell proliferation.
Since 1998, it has been generally accepted that MPL and other 
group I cytokine receptors exist as pre-formed dimers in the 
plasma membrane [40,59–64] and that TPO binding induces 
a conformational change in the MPL dimer, which is then propa-
gated by some mechanism across the plasma membrane to result 
in activation of the receptor-associated JAK2. The two non- 
identical MPL-binding sites, which are located on opposing 
faces of TPO (Figure 1(b-c)), are predicted to bind spatially 
similar surfaces on two separate molecules of MPL. The predicted 
TPO-binding site on MPL is located at the interface between the 
Ig-like and FnIII domains of CRM1. The ternary complex itself 
is, therefore, almost, but not perfectly symmetric. Local side- 
chain re-organization both within TPO and the MPL ECD is 
likely required to accommodate TPO binding and receptor dimer-
ization, in a similar manner to that observed for GH binding to 
GHR[33]. These conformational changes could contribute to sig-
naling across the plasma membrane; however, given the predicted 
flexibility of the intervening protein domains, such a mechanism 
seems unlikely. On the other hand, studies using artificially 
dimerized, chimeric MPL fusion proteins, in which the receptor 
ECD was replaced with a dimeric coiled coil derived from the 
S. cerevisiae transcriptional activator, Put364, have demonstrated 
that different orientations of the TM within the dimer display 
differences in signaling outcome. These differences in orientation 
are then transmitted to the ICD-associated JAK2, presumably 
bringing these into sufficiently close proximity to permit autopho-
sphorylation in trans and triggering phosphorylation of both the 
MPL ICD and downstream targets, including signal transducer 
and activator of transcription (STAT) proteins. Since the TM 
domain is the site of pathological mutations and the target of 
small molecule agonists, studies aimed at identifying mechanisms 
4 I. S. Hitchcock et al.                                                                                                             Platelets, Early Online: 1–9 
of activation have understandably focused on orientation and 
rotation of the TM helices. Enticingly, there are some suggestions 
that differences in TM helical orientation may alter activation 
status, and this may be responsible for the diversity of signaling 
output in different cell lineages [40,64]. However, focusing on 
TM polypeptides in isolation omits key physiological contexts 
relating to the full-length receptor and associated proteins, and 
the complex roles played by the plasma membrane.
In contrast, recent studies focusing on the full-length receptor 
expressed in cell lines suggest that MPL actually exists at the 
plasma membrane predominantly as monomers that dimerize in 
response to TPO [11,39,65,66]. Importantly, in cell lines expres-
sing MPL at physiologically relevant levels, TPO-driven receptor 
dimerization at the plasma membrane monitored by single- 
molecule imaging followed a bell-shaped dose–response curve, 
which was perfectly matched by phospho-STAT3 as a readout of 
downstream signaling, measured using single-cell flow cytometry 
[11]. This bell-shaped dose-response provides further support for 
ligand-induced receptor homodimerization via a two-step assem-
bly mechanism (as detailed in Figure 2(a-b) and below).
At physiological receptor densities and in the absence of TPO, 
MPL and the associated intracellular JAK2 are monomeric and 
inactive (Figure 2(a-d)). At low concentrations of TPO (below 
K1), most MPL at the cell surface are in the free form, whilst 
a small number are bound to TPO in a binary (1:1), non-signaling 
competent complex. As the concentration of TPO rises, the pro-
portion of binary complexes on the cell surface increases, and 
there is an increased likelihood that these will encounter a second 
MPL monomer and form a ternary (2:1 MPL:TPO), active com-
plex with the 2-dimensional binding affinity K2. Ternary complex 
formation and downstream signaling reach a maximum when the 
concentration of TPO equals K1. Finally, as the concentration of 
TPO exceeds K1, MPL monomers become saturated with TPO 
and binary non-signaling complexes again predominate.
Whilst maximum signaling occurs when the concentration of 
TPO equals K1, the width and amplitude of the bell-shaped curve 
are functions of K2 and receptor density[66]. An increase in the 
cell surface receptor concentration will broaden the curve and 
shift the EC50 to lower ligand concentrations, while a significant 
decrease in the receptor concentration will reduce the signaling 
amplitude and shift the EC50 to higher ligand concentration. The 
impact of receptor density on basal dimerization levels and sensi-
tivity to TPO has important implications for the interpretation of 
experimental data using cell-line overexpression models (Figure 2 
(c-d)). In these models, dimerization of MPL and downstream 
signaling in the absence of TPO, as well as hypersensitivity to 
Table I. Mutations in TPO and MPL associated with hematological disorders.













E204G*fs123, L269P*fs58 Thrombocytopenia [22]
TPO 5ʹ-UTR & 
splice sites 
(GOF)
intron 2 (position +2 T > C) 
intron 3 (G > C, A > G) 































(germline and somatic) 
L498W + H499C, H499G + V501S, H499Y + S505N, V501A + W515L/R, S505N 
+ T487A, S505N + S493C, S505N + V501A/M, S505N + Q516R, S505C + 
W515L, S505N + V501M + A506V











R541*, L594W, P635L CAMT [82,84,86]
Gain of Function (GOF), Loss of Function (LOF), congenital amegakaryocytic thrombocytopenia (CAMT), essential thrombocythemia (ET), primary 
myelofibrosis (PMF), acute megakaryoblastic leukemia (AMKL). Somatic mutations in bold. Residue numbers refer to the amino acid positions in 
the human TPO and MPL precursor proteins with Uniprot IDs P40225 and P40238, respectively, and thus include the signal peptide (see also 
Figure 1). 
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TPO may be observed simply as a result of the greater than 
physiological receptor density.[67]
Although the bridging of two MPL molecules by binding to 
one molecule of TPO was shown to provide the greatest energetic 
contribution to receptor dimerization [11], truncated receptors 
lacking the extracellular domain (and thus incapable of binding 
TPO) are also able to form dimers [11,65], suggesting that addi-
tional interactions, most likely within the TM-JM regions (see 
next section), contribute to dimer formation. Equally, receptor 
dimerization by TPO monitored by single-molecule imaging is 
further increased in the presence of JAK2, consistent with a role 
for the intracellular JAK2 in stabilizing the receptor dimer at the 
plasma membrane. Characterization of a series of JAK2 trunca-
tions demonstrated that both the FERM-SH2 module and adjoin-
ing pseudokinase (PK) domain were required, whilst the 
C-terminal tyrosine kinase domain was dispensable for receptor 
dimerization, although required for downstream signaling[11]. 
The affinities of these additional interfaces, although individually 
weak, and unable to support a stable dimer for wild-type proteins 
at low receptor density in the absence of TPO, can be enhanced 
by mutation to result in cytokine-independent dimerization 
(Figure 2(c-d) and see next section)[11]. These findings highlight 
the importance of receptor density and interactions between the 
receptor, plasma membrane and JAK2.
Pathological TPO Signaling in Hematological Disorders
Consistent with the critical role of the TPO-MPL signaling axis in 
HSC maintenance and proliferation, loss-of-function (LOF) and 
gain-of-function (GOF) mutations in TPO and MPL have been 
identified as underlying multiple hematological disorders (Figure 
1a, Table I) [77,92]. Aberrant signaling arising from GOF muta-
tions results in cellular hyperproliferation leading to hematologi-
cal malignancies, whilst LOF mutations result in 
thrombocytopenia and bone marrow failure[77]. A thorough 
understanding of the regulation of TPO-mediated signaling is 
important for the diagnosis and treatment of these diseases, whilst 
the nature of the disease-associated mutations provides insight on 
regulatory mechanisms. Dysregulation can occur at any of the 
levels through which the TPO-MPL signaling axis is controlled: 
from cytokine translation through cytokine and receptor traffick-
ing, secretion, receptor dimerization and downstream signaling.
Focusing first on TPO; (a) upregulation of THPO translation, and 
consequent increased serum TPO levels, resulting from point muta-
tions within the 5ʹ-untranslated region (UTR) that remove upstream 
AUG codons, is a causative factor in hereditary thrombocytosis [72– 
76]; whilst (b) point mutations (i.e. R99W [22,71]) and truncations 
(R31*[68], R157*[71]) within the MPL-binding domain, and frame-
shift mutations within the C-terminal glycan domain[22] result in 
reduced levels of serum TPO. These latter mutations are causal 
factors in hereditary thrombocytopenias and bone marrow failure 
syndromes, and are likely due to mutant protein degradation and/or 
trafficking defects, potentially caused by protein misfolding. By con-
trast, TPO R38C and R119C mutants show impaired receptor activa-
tion [69,70], possibly as a result of disulfide-mediated TPO dimer 
formation. Interestingly, R38, R99 and R119 are located on the sur-
face of TPO within the predicted MPL binding site 2 (Figure 1b and 
c), consistent with a reduced ability to form the ternary signaling 
complex. The relative paucity of disease-causing mutations identified 
thus far in THPO likely results from the essential nature of this 
cytokine.
In contrast, multiple LOF and GOF mutations have been mapped 
throughout the protein-coding sequence of MPL (Figure 1a, Table 
I). LOF is often associated with lack of receptor at the plasma 
membrane as a result of premature stop codons, point mutations 
that impair transcription (P136H), or cause defects in trafficking 
(K39N, R102P, P106L, W154R, R257C, P635L) (reviewed in Plo 
et al., 201777). Interestingly, R102P has been shown to result in both 
thrombocytopenia and thrombocytosis, depending on zygosity; in 
thrombocytosis patients heterozygous for MPL R102P, serum TPO 
levels were elevated, potentially a result of defective clearance 
driving hyperproliferation of HSCs expressing WT MPL[83]. 
Whilst MPL F104S reaches the cell surface, it shows a defect in 
TPO binding[84], as expected from the location of this residue in 
the predicted TPO binding site.
Mutations within the MPL TM and JM regions lead to cyto-
kine-independent growth in pre-clinical models [88,93,94] and 
comprise ~5-10% driver mutations in essential thrombocythemia 
(ET) and primary myelofibrosis (PMF)[95]. Oncogenic mutations 
at S505 and W515 have been shown to drive cytokine- 
independent dimerization via stabilization of the TM helix 
dimer interface [11,39,63,66]. Saturation mutagenesis of the TM 
region revealed multiple additional driver and ‘enhancer’ muta-
tions that occur at lower frequency in myeloproliferative neo-
plasm (MPN) patients [65,89], further highlighting the 
importance of this region to the active dimer interface.
In addition to mutations in MPL and TPO, multiple disease- 
associated mutations have been identified in the receptor- 
associated kinase JAK2 (reviewed in [96]). Here, we will briefly 
mention only JAK2 V617F, the most prevalent driver mutation in 
the classical MPNs[97]. JAK2 V617F has recently been shown to 
bestow cytokine-independence via dimerization of MPL-JAK2 
complexes in the absence of TPO through a novel interface within 
the JAK2 PK domain [11,98,99], thus demonstrating the potential 
for intracellular drivers of receptor dimerization.
In summary, GOF in MPL, TPO and its associated kinase 
JAK2 have been shown to result from changes that increase 
receptor dimerization either via direct stabilization of a dimer 
interface or via artificially increased levels of circulating TPO 
resulting from the dysregulation of negative feedback loops. On 
the other hand, LOF arises as a result of reduction in the levels of 
circulating TPO or of functional MPL at the plasma membrane 
(as illustrated in Figure 2(c-d)).
Perspectives and Concluding Remarks
Although our understanding of the role of the TPO-MPL signaling 
axis in health and disease has advanced considerably since their 
genes were cloned in the early 1990s, many questions remain. Not 
least among these is a more complete molecular understanding of 
receptor activation and signaling, which will be aided by molecular 
modeling approaches and the structures of intact signal-transduction 
complexes. The challenges of recombinant protein production com-
bined with full-length receptor and JAK flexibility have hampered 
structural studies to date; recent advances in electron cryo- 
microscopy, alongside solution techniques such as small-angle 
X-ray scattering [100], look set to deliver more detailed structural 
information in the near future. Equally, advances in single-molecule 
imaging have begun to illuminate receptor dynamics on the surface 
of living cells; however, these techniques have yet to be extended to 
allow imaging of receptors in their native context on platelets and 
HSCs. Technical improvements that have increased the sensitivity 
of biophysical techniques more generally will allow the determina-
tion of other key parameters, such as on/off rates and their relation-
ship to downstream signaling, using both live cells and recombinant 
material. How changes in cytokine-receptor complex half-life and 
endosomal trafficking fine-tunes cytokine signaling and biological 
responses requires further investigation.
Together, these new methods will provide a better understand-
ing of the molecular mechanism of MPL activation by TPO and 
open avenues to the development of novel strategies for the 
modulation of the pathway. In an important first step, Cui and 
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coworkers have recently discovered and characterized anti-MPL 
diabodies with differential effects on signaling output[101], which 
appear to separate the dual roles of MPL signaling; HSC self- 
renewal and megakaryocyte differentiation. As the development 
of highly specific synthetic cytokines gathers pace[102] it is 
tempting to speculate that additional modalities targeting the 
MPL ECD to alter signaling output could also be achieved.
As our understanding of TPO-MPL signaling evolves, it is 
now abundantly clear that we cannot consider receptor activation 
to be a binary “off” or “on”. Instead, it is a tightly regulated 
continuum, relying on the interplay between cytokine production, 
membrane receptor density and stability, transmembrane orienta-
tion and interactions with JAK2. However, this complexity may 
provide more diverse therapeutic targets, allowing the precise 
control of TPO signaling so as to improve HSC self-renewal 
and better regulate platelet production.
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